2023
43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial
Strober B, Kivitz A, Östör A, Padilla B, Yue C, Photowala H, Merola J. 43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial. Journal Of The American Academy Of Dermatology 2023, 89: ab179. DOI: 10.1016/j.jaad.2023.07.717.Peer-Reviewed Original Research
2020
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. Journal Of The European Academy Of Dermatology And Venereology 2020, 34: 2830-2838. PMID: 32320088, PMCID: PMC7818271, DOI: 10.1111/jdv.16521.Peer-Reviewed Original ResearchConceptsPrior biologic exposureSevere plaque psoriasisBaseline patient demographicsEfficacy of risankizumabPhase 3 trialDisease characteristicsWeek 16Logistic regression analysisPlaque psoriasisPatient demographicsBiologic exposureSuperior efficacyPlacebo-controlled phase 3 trialHumanized IgG monoclonal antibodyPrior biologic therapyProportion of patientsBody mass indexRegression analysisBaseline characteristicsBaseline demographicsBiologic therapyPsoriasis AreaWeek 52Patient characteristicsIgG monoclonal antibodies